Targeted and sustained drug delivery using PEGylated galactosylated liposomes

被引：51

作者：

Managit, C ^{[1
]}

Kawakami, S ^{[1
]}

Nishikawa, M ^{[1
]}

Yamashita, F ^{[1
]}

Hashida, M ^{[1
]}

机构：

[1] Kyoto Univ, Dept Drug Delivery Res, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2003年 / 266卷 / 1-2期

关键词：

sustained delivery; targeting; galactosylated liposomes; PEGylation; hepatocytes;

D O I：

10.1016/S0378-5173(03)00383-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To achieve a sustained and targeted delivery of liposomes to liver parenchymal cells (PC), we modified distearoyl-L-phosphatidylcholine (DSPC)/cholesterol (Chol) (60:40) (DSPC/Chol) liposomes with a galactosylated cholesterol derivative (Gal-C4-Chol), and polysorbate (Tween) 20 or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-polyethylene glycol (PEG,-DSPE). After intravenous injection, DSPC/Chol/Gal-C4-Chol (60:35:5) (Gal) liposomes were rapidly eliminated from the blood circulation and mostly recovered in the liver. The blood elimination of DSPC/Chol/Gal-C4-Chol/Tween 20 (55:35:5:5) (Tween 20-Gal) liposomes was slightly reduced as compared to Gal-liposomes. In contrast, a significant reduction in the blood elimination was observed with DSPC/Chol/Gal-C4-Chol/PEG(2000)-DSPE (59:35:5:1) (PEG(2000)-Gal) liposomes. Hepatic uptake of DSPC/Chol/Gal-C4-Chol/PEG(350)-DSPE (59:35:5:1) (PEG(350)-Gal) liposomes was intermediate between PEG(2000)-Gal-liposomes and Tween 20-Gal-liposomes. The uptake of PEG(350)-Gal-liposomes by liver PC was 7.7-fold higher than that by non-parenchymal cells (NPC). These results suggest that PEG(350)-DSPE can control the delivery rate of Gal-liposomes to liver PC without losing its targeting capability. (C) 2003 Elsevier B.V. All rights reserved.

引用

页码：77 / 84

页数：8

共 28 条

[1] LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].

ALLEN, TM ;

HANSEN, C ;

MARTIN, F ;

REDEMANN, C ;

YAUYOUNG, A .

BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36

[2]

Bhadra D, 2002, PHARMAZIE, V57, P5

[3]

DU H, 1997, BIOCHIM BIOPHYS ACTA, V1362, P236

[4]

Ghosh P C, 1991, Targeted Diagn Ther, V4, P87

[5]

HARA T, 1988, INT J PHARMACEUT, V42, P69

[6] Pegylation - A novel process for modifying pharmacokinetics [J].

Harris, JM ;

Martin, NE ;

Modi, M .

CLINICAL PHARMACOKINETICS, 2001, 40 (07) :539-551

[7] HEPATIC TARGETING OF DRUGS AND PROTEINS BY CHEMICAL MODIFICATION [J].

HASHIDA, M ;

NISHIKAWA, M ;

TAKAKURA, Y .

JOURNAL OF CONTROLLED RELEASE, 1995, 36 (1-2) :99-107

[8] Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting [J].

Hattori, Y ;

Kawakami, S ;

Yamashita, F ;

Hashida, M .

JOURNAL OF CONTROLLED RELEASE, 2000, 69 (03) :369-377

[9] Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo [J].

Ishida, O ;

Maruyama, K ;

Tanahashi, H ;

Iwatsuru, M ;

Sasaki, K ;

Eriguchi, M ;

Yanagie, H .

PHARMACEUTICAL RESEARCH, 2001, 18 (07) :1042-1048

[10] Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice [J].

Kawakami, S ;

Wong, J ;

Sato, A ;

Hattori, Y ;

Yamashita, F ;

Hashida, M .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2000, 1524 (2-3) :258-265

← 1 2 3 →